Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers

Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers

US Patent 8895001 · Granted Nov 25, 2014

Estimated economic value: $19,658,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Systems and methods for adversarial annotations2025
Carotenoid compositions and uses thereof2025
Alpha polyglutamated pemetrexed and uses thereof2025
Methods for treating pancreatic cancer using combination therapies2025
Gamma polyglutamated aminopterin and uses thereof2025
Alpha polyglutamated tetrahydrofolates and uses thereof2025
Alpha polyglutamated aminopterin and uses thereof2025
D glutamate polyglutamated antifolates and uses thereof2025
Gamma polyglutamated methotrexate and uses thereof2025
Alpha polyglutamated raltitrexed and uses thereof2025
Gamma polyglutamated pemetrexed and uses thereof2025
Alpha polyglutamated lometrexol and uses thereof2025